OSAKA, Japan, Sept. 30, 2011 /CNW/ - Takeda Pharmaceutical Company
Limited ("Takeda", TSE: 4502) announced it has completed its
acquisition of Nycomed A/S ("Nycomed") for 9.6 billion Euro on a
cash-free, debt-free basis and made Nycomed a wholly owned subsidiary
of Takeda effective the same day. Dr. Frank Morich has been named CEO
of Nycomed in addition to his current role as Executive Vice President
(EVP), International Operations (Americas/Europe), Takeda
Pharmaceuticals International, Inc., a wholly owned subsidiary of
Takeda America Holdings, Inc.
The transaction fits in with Takeda's sustainable growth strategy
outlined in its 2011-2013 Mid-Range Plan (MRP). Takeda has a strong
presence in the Japanese and U.S. markets, while Nycomed has a
significant business infrastructure in Europe and high-growth emerging
markets that will enhance Takeda's regulatory development expertise and
commercialization capability. In addition, the acquisition will bring
Takeda an immediate and stable increase in cash flow generated from
annual revenue of more than 2.8 billion Euro from the acquired
"The combination of both organizations will strengthen Takeda's
performance during the 2011-2013 MRP period, and enable us to sustain
medium and long-term growth targets starting in fiscal 2015 and
extending into the next decade," said Yasuchika Hasegawa, President &
CEO of Takeda. "Partnering the two organizations will have
complementary effects and further increase our potential to become a
truly global pharmaceutical company."
"I look forward to bringing Takeda and Nycomed together to ensure we can
achieve enhanced revenue, growth and diversification, while maintaining
the strong momentum of both companies," said Frank Morich. "The
combined company significantly broadens our coverage of the global
pharmaceutical market to more than 70 countries, increasing our global
Rx sales ranking to 12th and further strengthening our position in the
The combined company will have an active commercial presence in the
therapeutic areas of metabolic diseases, gastroenterology, oncology,
cardiovascular health, CNS diseases, inflammatory and immune disorders,
respiratory diseases and pain management, as well as having a
well-balanced presence in pharmaceutical markets of Japan, North
America, Europe and Asia/Emerging Markets.
The integration enhances the 1,260 billion yen of projected FY 2013
sales in 2011-13 MRP by more than 30 percent and improves the 280
billion yen of projected FY 2013 operating income (excluding special
factors derived from business acquisition) in 2011-13 MRP by more than
40 percent. Takeda will now start preparation of the consolidated
financial outlook for its fiscal 2011 ending March 31, 2012, and is
planning to announce it upon announcement of its financial results of
fiscal 2011 2Q scheduled in November.
Located in Osaka, Japan, Takeda is a research-based global company with
its main focus on pharmaceuticals. As the largest pharmaceutical
company in Japan and one of the global leaders of the industry, Takeda
is committed to strive towards better health for patients worldwide
through leading innovation in medicine. Additional information about
Takeda is available through its corporate website, http://www.takeda.com.
Takeda's Forward-looking statements
This press release contains forward-looking statements. Forward-looking
statements include statements regarding Takeda's plans, outlook,
strategies, results for the future, and other statements that are not
descriptions of historical facts. Forward-looking statements may be
identified by the use of forward-looking words such as "may,"
"believe," "will," "expect," "project," "estimate," "should,"
"anticipate," "plan," "assume," "continue," "seek," "pro forma,"
"potential," "target," "forecast," "guidance," "outlook" or "intend" or
other similar words or expressions of the negative thereof.
Forward-looking statements are based on estimates and assumptions made
by management that are believed to be reasonable, though they are
inherently uncertain and difficult to predict. Investors are cautioned
not to unduly rely on such forward-looking statements.
Forward-looking statements involve risks and uncertainties that could
cause actual results or experience to differ materially from that
expressed or implied by the forward-looking statements. Some of these
risks and uncertainties include, but are not limited to, (1) the
economic circumstances surrounding Takeda's business, including general
economic conditions in Japan, the United States and worldwide; (2)
competitive pressures and developments; (3) applicable laws and
regulations; (4) the success or failure of product development
programs; (5) actions of regulatory authorities and the timing thereof;
(6) changes in exchange rates; (7) claims or concerns regarding the
safety or efficacy of marketed products or product candidates in
development; and (8) integration activities with acquired companies.
The forward-looking statements contained in this press release speak
only as of the date of this press release, and Takeda undertakes no
obligation to revise or update any forward-looking statements to
reflect new information, future events or circumstances after the date
of the forward-looking statement. If Takeda does update or correct one
or more of these statements, investors and others should not conclude
that Takeda will make additional updates or corrections.
SOURCE Takeda Pharmaceutical Company Limited
For further information:
Takeda Media and Investor Contacts:
For Japanese Media and Global IR Inquiries:
For Media Inquiries: